ES2765573T3 - Tratamiento y diagnóstico de melanoma - Google Patents

Tratamiento y diagnóstico de melanoma Download PDF

Info

Publication number
ES2765573T3
ES2765573T3 ES13829165T ES13829165T ES2765573T3 ES 2765573 T3 ES2765573 T3 ES 2765573T3 ES 13829165 T ES13829165 T ES 13829165T ES 13829165 T ES13829165 T ES 13829165T ES 2765573 T3 ES2765573 T3 ES 2765573T3
Authority
ES
Spain
Prior art keywords
alkyl
cells
cancer
mir
melanoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13829165T
Other languages
English (en)
Spanish (es)
Inventor
Sohail Tavazoie
Nora G Pencheva
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rockefeller University
Original Assignee
Rockefeller University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rockefeller University filed Critical Rockefeller University
Application granted granted Critical
Publication of ES2765573T3 publication Critical patent/ES2765573T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Emergency Medicine (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biophysics (AREA)
ES13829165T 2012-08-13 2013-08-13 Tratamiento y diagnóstico de melanoma Active ES2765573T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261682339P 2012-08-13 2012-08-13
US201361784057P 2013-03-14 2013-03-14
PCT/US2013/054690 WO2014028461A2 (en) 2012-08-13 2013-08-13 Treatment and diagnosis of melanoma

Publications (1)

Publication Number Publication Date
ES2765573T3 true ES2765573T3 (es) 2020-06-09

Family

ID=50101591

Family Applications (2)

Application Number Title Priority Date Filing Date
ES13829165T Active ES2765573T3 (es) 2012-08-13 2013-08-13 Tratamiento y diagnóstico de melanoma
ES19189895T Active ES2941477T3 (es) 2012-08-13 2013-08-13 Agonista de LXRbeta para el tratamiento de cáncer

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES19189895T Active ES2941477T3 (es) 2012-08-13 2013-08-13 Agonista de LXRbeta para el tratamiento de cáncer

Country Status (10)

Country Link
US (8) US9399028B2 (enExample)
EP (3) EP4218935A1 (enExample)
JP (5) JP6320382B2 (enExample)
CN (3) CN116271053A (enExample)
AU (4) AU2013302861A1 (enExample)
CA (2) CA3211094A1 (enExample)
DK (1) DK2882496T3 (enExample)
ES (2) ES2765573T3 (enExample)
HU (1) HUE046292T2 (enExample)
WO (1) WO2014028461A2 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2724322C (en) 2008-05-14 2019-07-16 Dermtech International Diagnosis of melanoma and solar lentigo by nucleic acid analysis
PL2820013T3 (pl) 2012-03-02 2019-01-31 Ralexar Therapeutics, Inc. Modulatory receptorów X wątroby (LXR) do leczenia chorób, zaburzeń i stanów skórnych
HUE046292T2 (hu) * 2012-08-13 2020-02-28 Univ Rockefeller Melanóma kezelése és diagnosztizálása
ES2804304T3 (es) 2013-09-04 2021-02-05 Ellora Therapeutics Inc Moduladores del receptor X hepático (LXR)
SG11201601644RA (en) 2013-09-04 2016-04-28 Alexar Therapeutics Inc Liver x receptor (lxr) modulators
AU2015204572B2 (en) * 2014-01-10 2020-07-30 Inspirna, Inc. LXR agonists and uses thereof
WO2016179043A1 (en) 2015-05-01 2016-11-10 Dermtech, Inc. Non-invasive skin collection system
US20190125745A1 (en) * 2014-12-17 2019-05-02 Rgenix, Inc. Treatment and diagnosis of cancer
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
AU2016281776B2 (en) * 2015-06-24 2019-09-05 Oxford BioDynamics PLC Detection processes using sites of chromosome interaction
US20200046671A1 (en) * 2015-06-29 2020-02-13 Regents Of The University Of Minnesota Apobec3b mutagenesis and immunotherapy
EP3313993A4 (en) 2015-06-29 2019-06-19 Regents of the University of Minnesota ANTI-APOBEC3 ANTIBODIES AND METHOD OF PREPARATION AND USE
JP7025022B2 (ja) * 2016-01-11 2022-02-24 ザ ロックフェラー ユニバーシティー 骨髄系由来抑制細胞関連障害の治療のための方法
EP3416668A4 (en) 2016-02-18 2020-02-19 The Wistar Institute Of Anatomy And Biology METHODS AND COMPOSITIONS FOR THE TREATMENT OF MELANOMA
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI822521B (zh) * 2016-05-13 2023-11-11 美商再生元醫藥公司 藉由投予pd-1抑制劑治療皮膚癌之方法
CN109689062B (zh) * 2016-07-11 2023-02-17 丹娜法伯癌症研究院 使用抗PI3Kβ和抗免疫检查点药剂的组合治疗PTEN缺陷型上皮癌的方法
JP7300394B2 (ja) 2017-01-17 2023-06-29 ヘパリジェニックス ゲーエムベーハー 肝再生の促進又は肝細胞死の低減もしくは予防のためのプロテインキナーゼ阻害
WO2018161054A1 (en) * 2017-03-03 2018-09-07 Rgenix, Inc. Formulations with improved stability
CN106890315B (zh) * 2017-03-16 2019-09-06 北京热休生物技术有限公司 Apo-e蛋白及其多肽在治疗与预防癌症中的应用
US20210085663A1 (en) * 2017-05-16 2021-03-25 Biomed Valley Discoveries, Inc. Compositions and methods for treating cancer with atypical braf mutations
AU2018373028A1 (en) 2017-11-21 2020-04-30 Inspirna, Inc. Polymorphs and uses thereof
EP3752645A4 (en) 2018-02-14 2022-04-13 Dermtech, Inc. Novel gene classifiers and uses thereof in non-melanoma skin cancers
MX2021006253A (es) * 2018-11-28 2021-09-21 Prevail Therapeutics Inc Terapias génicas para enfermedad neurodegenerativa.
US20220127680A1 (en) * 2019-02-28 2022-04-28 The Rockefeller Universtiy Apoe genotyping in cancer prognostics and treatment
AU2020247911A1 (en) 2019-03-26 2021-11-11 Dermtech, Llc Novel gene classifiers and uses thereof in skin cancers
JP2022530845A (ja) * 2019-04-27 2022-07-04 オクジェン アイエヌシー． 眼疾患に対するａｄｅｎｏ随伴ウイルス連ウイルスベクター媒介遺伝子治療
CN110218235B (zh) * 2019-05-09 2020-09-25 中山大学 一种化合物及其制备方法和作为荧光偏振探针在LXRβ配体筛选中的应用
EP4027989A4 (en) * 2019-09-11 2023-09-06 Inspirna, Inc. METHOD FOR TREATING CANCER
US20220339184A1 (en) * 2019-09-27 2022-10-27 The Rockefeller University Compositions and methods to treat metastatic gastrointestinal cancer
RU2716811C1 (ru) * 2019-11-14 2020-03-16 федеральное государственное бюджетное образовательное учреждение высшего образования "Новгородский государственный университет имени Ярослава Мудрого" Способ ранней диагностики поверхностно распространяющихся меланом
PL4073025T3 (pl) 2019-12-13 2024-09-16 Inspirna, Inc. Sole metali i ich zastosowania
CA3162845A1 (en) * 2019-12-23 2021-07-01 Anastasia Khvorova Oligonucleotides for tissue specific gene expression modulation
KR20230052970A (ko) * 2020-08-21 2023-04-20 체에스엘 베링 아게 헤모펙신:헴 복합체를 검출하는데 사용하기 위한 cd91 폴리펩타이드
EP4376953A1 (en) * 2021-07-30 2024-06-05 Alnylam Pharmaceuticals, Inc. Peptide ligands for cns and ocular delivery of rnai compounds
CN114276999A (zh) * 2022-03-03 2022-04-05 中日友好医院(中日友好临床医学研究所) 黑素瘤细胞株及其制备方法

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5324731A (en) 1989-02-14 1994-06-28 Amira, Inc. Method of inhibiting transformation of cells in which purine metabolic enzyme activity is elevated
US5676978A (en) 1989-02-14 1997-10-14 Amira, Inc. Methods of inhibiting undesirable cell growth using a combination of a cyclocreatine compound and a hyperplastic inhibitory agent
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5215882A (en) 1989-11-30 1993-06-01 Ortho Diagnostic Systems, Inc. Method of immobilizing nucleic acid on a solid surface for use in nucleic acid hybridization assays
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5837832A (en) 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US5707807A (en) 1995-03-28 1998-01-13 Research Development Corporation Of Japan Molecular indexing for expressed gene analysis
US5843974A (en) * 1995-06-06 1998-12-01 Eli Lilly And Company Methods of inhibiting melanoma using Benzothiophenes as cytotoxic agents per se
US5958342A (en) 1996-05-17 1999-09-28 Incyte Pharmaceuticals, Inc. Jet droplet device
US6060240A (en) 1996-12-13 2000-05-09 Arcaris, Inc. Methods for measuring relative amounts of nucleic acids in a complex mixture and retrieval of specific sequences therefrom
US6090556A (en) 1997-04-07 2000-07-18 Japan Science & Technology Corporation Method for quantitatively determining the expression of a gene
US5994076A (en) 1997-05-21 1999-11-30 Clontech Laboratories, Inc. Methods of assaying differential expression
DE69835766T2 (de) 1997-12-12 2007-09-13 University of Western Ontario, Ontario Neues peptid, apoep1.b, zusammensetzungen und verwendungen davon
US6004755A (en) 1998-04-07 1999-12-21 Incyte Pharmaceuticals, Inc. Quantitative microarray hybridizaton assays
US6048695A (en) 1998-05-04 2000-04-11 Baylor College Of Medicine Chemically modified nucleic acids and methods for coupling nucleic acids to solid support
US6087112A (en) 1998-12-30 2000-07-11 Oligos Etc. Inc. Arrays with modified oligonucleotide and polynucleotide compositions
US6316503B1 (en) 1999-03-15 2001-11-13 Tularik Inc. LXR modulators
US8257750B2 (en) 1999-04-30 2012-09-04 Kibow Biotech, Inc. Calcium carbonate compositions for preventing or treating hyperphosphatemia
US6716622B2 (en) 2000-07-18 2004-04-06 Uab Research Foundation Tissue-specific self-inactivating gene therapy vector
AU2001288955A1 (en) 2000-09-07 2002-03-22 Vanderbilt University Genome engineering by cell-permeable dna site-specific recombinases
WO2002024632A2 (en) 2000-09-18 2002-03-28 Glaxo Group Limited Substituted aminopropoxyaryl derivatives useful as agonists for lxr
WO2002048197A1 (en) 2000-12-13 2002-06-20 Sca Hygiene Products Zeist B.V. Process for oxidising primary alcohols
JP2003033179A (ja) 2001-07-05 2003-02-04 Asahi Kasei Corp 可逆的遺伝子導入ベクター
JP4471842B2 (ja) * 2002-03-27 2010-06-02 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー アミド化合物および該化合物を用いる方法
JP2005521721A (ja) 2002-03-27 2005-07-21 スミスクライン・ビーチャム・コーポレイション 酸およびエステル化合物ならびにその使用方法
AU2003226094A1 (en) 2002-03-27 2003-10-13 Smithkline Beecham Corporation Compounds and methods
US7476519B2 (en) 2002-07-19 2009-01-13 Joseph Monforte Strategies for gene expression analysis
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US20040216178A1 (en) 2003-03-03 2004-10-28 Jones Stephen N Regulation of mdm2 function
US20050130919A1 (en) 2003-07-18 2005-06-16 University Of Massachusetts Regulatable promoters for synthesis of small hairpin RNA
WO2005039643A2 (en) 2003-10-20 2005-05-06 Nsgene A/S In vivo gene therapy of parkinson's disease
PA8619901A1 (es) 2003-12-12 2005-11-25 Wyeth Corp Quinolinas utiles en el tratamiento de enfermedades cardiovasculares
FR2865736B1 (fr) 2004-02-02 2006-07-14 Synt Em Inhibiteurs de l'angiogenese, compositions les contenant et leur utilisation pour le traitement des maladies liees a une deregulation de l'angiogenese
WO2005112620A2 (en) 2004-05-18 2005-12-01 Massachusetts Institute Of Technology A cre-lox based method for conditional rna interference
CA2572872C (en) * 2004-07-02 2013-10-22 Sankyo Company Limited Tissue factor production inhibitor
CN1980665A (zh) 2004-07-07 2007-06-13 默克公司 吡唑酰胺衍生物，包含这些化合物的组合物和使用方法
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
WO2006037480A1 (en) 2004-10-01 2006-04-13 F.Hoffmann-La Roche Ag Hexafluoroisopropanol substituted ether derivatives
MX2007007433A (es) 2004-12-22 2007-07-17 Hoffmann La Roche Nuevos derivados de ciclohexano.
RU2007130152A (ru) 2005-01-10 2009-02-20 Астразенека Аб (Se) Производные 1, 1-диоксидов изотиазол-3(2h)-онов в качестве модуляторов печеночных х-рецепторов
JP2008526842A (ja) 2005-01-10 2008-07-24 アストラゼネカ アクチボラグ 肝ｘ受容体モジュレーターとしてのイソチアゾール−３（２ｈ）−チオン１，１−ジオキシドのアニリン誘導体
SE0500055D0 (sv) 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 3
SE0500056D0 (sv) 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 4
SE0500058D0 (sv) 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 5
WO2006094034A1 (en) 2005-03-01 2006-09-08 Wyeth Cinnoline compounds and their use as liver x receptor modilators
US8318760B2 (en) 2005-03-21 2012-11-27 Merck Sharp & Dohme Corp. Substituted aryl and heteroaryl derivatives, compositions containing such compounds and methods of use
NZ564916A (en) 2005-06-27 2011-03-31 Exelixis Inc Imidazole based LXR modulators
ATE504565T1 (de) 2005-10-07 2011-04-15 Exelixis Inc Azetidine als mek-inhibitoren bei der behandlung proliferativer erkrankungen
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7790745B2 (en) 2005-10-21 2010-09-07 Bristol-Myers Squibb Company Tetrahydroisoquinoline LXR Modulators
WO2007092065A2 (en) 2005-11-14 2007-08-16 Irm Llc Compounds and compositions as lxr modulators
WO2007081335A1 (en) 2006-01-12 2007-07-19 Merck & Co., Inc. Therapeutic compounds for treating dyslipidemic conditions
WO2007108749A1 (en) 2006-03-20 2007-09-27 Cepep Iii Ab Chimeric constructs between cancer-homing peptides and cell-penetrating peptides coupled to anticancer drugs and/or diagnostic agent/agents
WO2008011071A2 (en) * 2006-07-19 2008-01-24 The Regents Of The University Of California Interactions of hedgehog and liver x receptor signaling pathways
TW200825054A (en) 2006-10-18 2008-06-16 Wyeth Corp Quinoline compounds
US8324367B2 (en) 2006-11-03 2012-12-04 Medtronic, Inc. Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity
EP2098515B1 (en) 2006-11-30 2012-02-08 Kowa Company, Ltd. Substituted carbinol compound
KR20090094125A (ko) 2006-12-08 2009-09-03 엑셀리시스, 인코포레이티드 Ｌｘｒ 및 ｆｘｒ 조절자
JP2008179562A (ja) 2007-01-24 2008-08-07 Kowa Co Ｌｘｒアゴニスト
US8993628B2 (en) 2007-02-23 2015-03-31 City Of Hope Synthetic ligands selective for LXRβ over LXRα, identification and methods of use thereof
JP2010527930A (ja) 2007-05-18 2010-08-19 ワイス・エルエルシー キナゾリン化合物
CA2691673A1 (en) 2007-06-29 2009-01-08 Avi Biopharma, Inc. Tissue specific peptide conjugates and methods
ES2393822T3 (es) 2007-08-13 2012-12-28 F. Hoffmann-La Roche Ag Nuevos derivados de piperazina-amida
TW200922582A (en) 2007-08-20 2009-06-01 Organon Nv N-benzyl, N'-arylcarbonylpiperazine derivatives
US8039493B2 (en) 2007-09-27 2011-10-18 Hoffmann-La Roche Inc. Biaryl sulfonamide derivatives
KR101889518B1 (ko) * 2007-10-04 2018-08-17 로슈 이노베이션 센터 코펜하겐 에이/에스 마이크로ＭＩＲｓ
CN101918030B (zh) 2007-11-09 2015-10-14 派瑞格恩医药公司 抗vegf抗体的组合物和方法
US8236753B2 (en) * 2007-12-10 2012-08-07 The Brigham And Women's Hospital, Inc. RAP variants for drug delivery and methods of use thereof
MX2010007019A (es) 2007-12-21 2010-08-18 Wyeth Llc Compuestos de bencimidazol.
US20100331333A1 (en) 2007-12-21 2010-12-30 Wyeth Llc Imidazo [1,2-B] Pyridazine Compounds
BRPI0822237A2 (pt) 2007-12-21 2015-06-30 Wyeth Llc Compostos de imidazo [1,2-a] piridina
AU2008345687A1 (en) 2007-12-21 2009-07-09 Wyeth Llc Pyrazolo [1,5-a] pyrimidine compounds
WO2009107387A1 (ja) 2008-02-29 2009-09-03 興和株式会社 ２－オキソクロメン誘導体
MX2010012579A (es) * 2008-05-29 2010-12-20 Squibb Bristol Myers Co Metodos para predecir respuesta de pacientes a modulacion de la via co-estimuladora.
WO2010002982A1 (en) * 2008-07-01 2010-01-07 Cognosci, Inc. Methods of treating cancer with apoe peptides
MX2011003195A (es) 2008-09-26 2011-08-12 Dana Farber Cancer Inst Inc Anticuerpos anti-pd-1, pd-l1 y pd-l2 humanos y usos de los mismos.
WO2010101888A2 (en) * 2009-03-02 2010-09-10 Biocure Pharma, Llc Methods and compositions for treatment of tumor metastasis
SI2435410T1 (sl) * 2009-05-28 2017-06-30 Bristol-Myers Squibb Company Lxr modulatorji
WO2011115892A1 (en) * 2010-03-15 2011-09-22 Griffin Patrick R Modulators of the retinoic acid receptor-related orphan receptors
WO2011130426A2 (en) * 2010-04-13 2011-10-20 New York University Compositions and methods for treatment of melanoma
CN102947468B (zh) 2010-06-16 2014-03-19 国立大学法人浜松医科大学 大肠肿瘤的检测方法
EP2474617A1 (en) * 2011-01-11 2012-07-11 InteRNA Technologies BV Mir for treating neo-angiogenesis
US20130004481A1 (en) * 2011-01-12 2013-01-03 Boehringer Ingelheim International Gmbh Anticancer therapy
TW201242953A (en) 2011-03-25 2012-11-01 Bristol Myers Squibb Co Imidazole prodrug LXR modulators
WO2013043569A1 (en) * 2011-09-20 2013-03-28 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
HUE046292T2 (hu) * 2012-08-13 2020-02-28 Univ Rockefeller Melanóma kezelése és diagnosztizálása

Also Published As

Publication number Publication date
US20150023955A1 (en) 2015-01-22
US9962348B2 (en) 2018-05-08
EP2882496B1 (en) 2019-10-09
JP6523502B2 (ja) 2019-06-05
WO2014028461A2 (en) 2014-02-20
US9526710B2 (en) 2016-12-27
JP7005551B2 (ja) 2022-02-04
CA3211094A1 (en) 2014-02-20
CN104780976B (zh) 2019-01-01
US20170319525A1 (en) 2017-11-09
US9707195B2 (en) 2017-07-18
JP7472080B2 (ja) 2024-04-22
AU2022215282A1 (en) 2022-11-03
CN110037999A (zh) 2019-07-23
JP2024041827A (ja) 2024-03-27
AU2013302861A1 (en) 2015-03-05
CN116271053A (zh) 2023-06-23
EP2882496A2 (en) 2015-06-17
US20240252458A1 (en) 2024-08-01
WO2014028461A3 (en) 2014-04-17
EP4218935A1 (en) 2023-08-02
CN110037999B (zh) 2023-01-13
US11865094B2 (en) 2024-01-09
CN104780976A (zh) 2015-07-15
CA2882292C (en) 2023-10-17
JP2022001571A (ja) 2022-01-06
HUE046292T2 (hu) 2020-02-28
US20200230090A1 (en) 2020-07-23
AU2018226488A1 (en) 2018-09-27
US9399028B2 (en) 2016-07-26
US12502368B2 (en) 2025-12-23
JP2019151646A (ja) 2019-09-12
CA2882292A1 (en) 2014-02-20
AU2020200715B2 (en) 2022-05-12
EP3626309B1 (en) 2023-03-08
US20160331726A1 (en) 2016-11-17
AU2018226488B2 (en) 2020-01-23
US20180153833A1 (en) 2018-06-07
ES2941477T3 (es) 2023-05-23
AU2020200715A1 (en) 2020-02-20
DK2882496T3 (da) 2019-11-11
JP2015532642A (ja) 2015-11-12
HK1212273A1 (en) 2016-06-10
EP2882496A4 (en) 2016-07-06
JP6320382B2 (ja) 2018-05-09
EP3626309A1 (en) 2020-03-25
US20150073053A1 (en) 2015-03-12
US10543183B2 (en) 2020-01-28
US20210220306A1 (en) 2021-07-22
US10945978B2 (en) 2021-03-16
JP2018140982A (ja) 2018-09-13

Similar Documents

Publication Publication Date Title
ES2765573T3 (es) Tratamiento y diagnóstico de melanoma
HK40005229A (en) Treatment and diagnosis of melanoma
HK40005229B (en) Treatment and diagnosis of melanoma
HK1212273B (zh) 治疗和诊断黑素瘤